Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Absci has raised $100.0M in total funding. The most recent round was Post-IPO Equity. The last funding was announced in June 2026.
Absci's investors include Eli Lilly, AMD, Redmile Group, Perceptive Advisors, Fidelity.
Absci is headquartered in Vancouver, United States.
Absci is the drug & target discovery company harnessing deep learning AI & synthetic biology to expand the therapeutic potential of proteins
Absci is at the Post-IPO Equity stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Absci — Funding & Investors." VCBacked, June 24, 2026, https://www.vcbacked.co/company/absci. Accessed November 12, 2026.
VCBacked. (2026). Absci — Funding & Investors. Retrieved November 12, 2026, from https://www.vcbacked.co/company/absci
{{cite web |title=Absci — Funding & Investors |url=https://www.vcbacked.co/company/absci |website=VCBacked |access-date=November 12, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated
Work at Absci? Request a listing update